SOURCE: Chembio Diagnostics, Inc.

April 03, 2007 09:00 ET

Chembio to Host Conference Call Today at 4:30pm EDT to Discuss Financial Results for 2006

MEDFORD, NY -- (MARKET WIRE) -- April 3, 2007 -- Chembio Diagnostics, Inc. (OTCBB: CEMI) will host a conference call Today, Tuesday, April 3, 2006 at 4:30pm EDT to discuss the reported fourth quarter and full-year financial results for 2006.

Chembio invites all those interested in hearing management's discussion of the financial results to join the call by dialing (877) 407-0782. International participants may access the call by dialing (201) 689-8567.

A live webcast can be accessed by clicking on the following link A recording of this webcast can also be accessed by using the same link.


Chembio Diagnostics, Inc. is a developer and manufacturer of rapid diagnostic tests for infectious diseases. The Company has received marketing approval from the FDA for two of its rapid HIV tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. References to Chembio may also include its wholly owned operating subsidiary, Chembio Diagnostic Systems, Inc. For additional information please visit


Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact Information

  • Contact:
    Chembio Diagnostics, Inc.
    Matty Arce
    (631) 924-1135 ext. 123